Latest Intelligence on Immunology and Inflammation

Published within

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Psoriasis market: Humira set to overtake Enbrel

Published By Datamonitor
22 Jan 2007
Expert View
Expert View

Proteins in peril

Published By Datamonitor
10 Aug 2001
CommentWire
CommentWire

Pharmacia: increasing its domination in pain

It's been a busy week for Pharmacia in pain management. Injectable Dynastat has been approved in Europe, while oral Bextra has launched in the US. Both drugs have significant advantages over existing therapies, and they complement each other well. Together, they will help Pharmacia tighten its grip on the $17 billion pain market.

Published By Datamonitor
11 Apr 2002
CommentWire
CommentWire

Pfizer: stacking up positive data for new rheumatoid arthritis drug

Positive results from a second Phase III trial take Pfizer's tofacitinib one step closer to becoming the first novel oral small molecule for the treatment of rheumatoid arthritis. While these data contribute to tofacitinib's clinical and commercial offering, pricing and product positioning remains a concern. Nonetheless Datamonitor views tofacitinib as a future blockbuster in rheumatoid arthritis.

Published By Datamonitor
07 Mar 2011
CommentWire
CommentWire

Pfizer: promising news for rheumatoid arthritis drug but pricing will be crucial

Promising Phase III rheumatoid arthritis data for Pfizer's oral tasocitinib are set to emerge at this year's American College of Rheumatology meeting. As a first-in-class drug with the potential to address the unmet need for oral small molecules to treat rheumatoid arthritis, Datamonitor believes that it will have a distinct advantage. However, reasonable pricing will be crucial to its success.

Published By Datamonitor
08 Nov 2010
CommentWire
CommentWire

Pfizer: no immediate threat to Celebrex from generics

The threat of generic competition to Celebrex has diminished after patents covering the drug were upheld. Teva will not be allowed to file for a copycat version of the drug until 2015 and other generics manufacturers are now unlikely to contest its patents before expiry. Celebrex's market leading position is also unlikely to be challenged by the forthcoming launch of competing COX-2 products.

Published By Datamonitor
22 Mar 2007
CommentWire
CommentWire

Pfizer: Last gasp for Exubera

Suffering with disappointing sales, Pfizer has abandoned its inhaled insulin product Exubera, a decision which will result in a $2.8 billion write-off. Despite being touted as the next big thing by most analysts, Datamonitor recognized that a number of issues plagued the inhaled insulin class issues which other companies developing similar products must overcome in order to avoid the same fate.

Published By Datamonitor
18 Oct 2007
CommentWire
CommentWire

Pfizer: FDA request may delay tofacitinib's approval but hopes for the drug remain undiminished

The latest trial results for Pfizer's tofacitinib add to the drug's wealth of clinical data as it sits on the brink of US entry. Nevertheless, Pfizer has revealed that the FDA has requested further data analysis on tofacitinib. While this is likely to extend the FDA's period of review, Datamonitor continues to anticipate tofacitinib's US launch in Q1 2013.

Published By Datamonitor
02 Aug 2012
Expert View
Expert View

Pfizer: expanding consumer health business through OTC Nexium deal

Recently, Pfizer and AstraZeneca announced that they have signed a deal giving Pfizer marketing rights for the OTC version of the gastroesophageal reflux disease drug Nexium. Along with the cash-generating potential, the deal also strengthens Pfizer's consumer healthcare division, which can act synergistically with the company's innovative pharma business, especially in the emerging markets.

Published By Datamonitor
22 Aug 2012
CommentWire
CommentWire

Pfizer: defining invention

The University of Rochester sued Pfizer [PFZ.L] in 2000 claiming infringement of its patent covering COX-2 inhibitors, but has now lost in appeal. This case has parallels with another case that Pfizer is fighting. However, the dispute over Viagra patents sees Pfizer on the other side of the fence. Pfizer may come to regret the precedent set in this particular case.

Published By Datamonitor
20 Feb 2004

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

No help is available.